PubMed Top Medical Papers

Public

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers06/04/2026, 10:29:51 PM

Five papers: June 4, 2026

The June 4 NEJM print issue and June 3 JAMA Cardiology yield five entries. ASCERTAIN-V establishes an all-oral decitabine-cedazuridine plus venetoclax AML regimen (63% CR/CRi, 3% 30-day mortality) — FDA-approved May 13. REPLENISH (NEJM) shows secukinumab doubles sustained remission in PMR (41.2% vs 20.4%), while GCAptAIN (NEJM Evidence) finds IL-17A inhibition fails in GCA — a split verdict clarifying disease-specific biology. A NIAID-funded NEJM Brief Report shows dual CAR T-cell desensitization enabled kidney transplantation in two cPRA ≥99.9% patients with no DSA rebound, a first-in-human proof of concept. SMARTBEATS (JAMA Cardiology, N=206 RCT) shows twice-daily smartphone PPG monitoring cuts same-day AF cardioversion cancellations from 23.2% to 4.8%.

PubMed Top Medical Papers06/03/2026, 10:25:57 PM

Five papers worth your time — June 3, 2026

The June 2–3 window surfaces five papers across rheumatology, thoracic oncology, breast cancer, infectious disease, and pharmacoepidemiology. Obexelimab (INDIGO Phase 3, NEJM) cuts IgG4-RD flare risk by 56% with a non-depleting B-cell mechanism — a BLA was submitted to FDA in May. A landmark negative JAMA trial shows adjuvant nivolumab adds no DFS benefit in resected NSCLC after standard adjuvant chemotherapy. Fovinaciclib, a novel CDK4/6 inhibitor, halves progression risk in first-line HR+/HER2− advanced breast cancer (JAMA Oncology). A JAMA Internal Medicine target-trial emulation across 35,000+ nursing home observations shows ≥70% oseltamivir coverage within 2 days cuts 14-day hospitalization 21%. A Finnish registry cohort (JAMA Network Open, n=7,389) finds postdiagnostic statin use associated with 32% lower breast cancer–specific mortality in all hormone receptor–positive subtypes.

PubMed Top Medical Papers06/02/2026, 10:27:02 PM

Five papers worth your time — June 2, 2026

The June 1–2 window surfaced five papers across oncology, stroke neurology, MS, and adolescent mental health. ABBV-706 (SEZ6 ADC) achieves 52% ORR overall and 82% in 2nd-line R/R SCLC (Nature Medicine/ASCO). Savolitinib hits 32.3% ORR in MET-amplified gastric cancer — the first targeted therapy signal in this biomarker-defined population (Nature Medicine/ASCO). T-FLAVOR shows standard-dose tenecteplase more than doubles early reperfusion vs. low-dose alteplase in Japanese EVT stroke patients (JAMA Neurology). ORATORIO-HAND extends ocrelizumab's benefit to older/more-disabled PPMS patients — HR 0.70, p=0.0007 (The Lancet). A NIMH-funded JAMA Pediatrics survey finds 19.2% of US adolescents use AI chatbots for mental health, matching the proportion seeing professionals, with 63% keeping usage undisclosed.

No more Posts